Luminex (LMNX) 10-Q 6 Nov 20 2020 Q3 Quarterly report Financial data

COVER PAGE Document

COVER PAGE Document - shares	9 Months Ended
	Sep. 30, 2020	Nov. 05, 2020
COVER PAGE [Abstract]
Entity Central Index Key	0001033905
Entity Filer Category	Large Accelerated Filer
Entity Current Reporting Status	Yes
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	LMNX
City Area Code	(512)
Entity Address, Address Line One	12212 Technology Blvd.,
Entity Incorporation, State or Country Code	DE
Entity File Number	000-30109
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2020
Document Transition Report	false
Entity Registrant Name	LUMINEX CORPORATION
Entity Tax Identification Number	74-2747608
Entity Address, City or Town	Austin,
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	78727
Local Phone Number	219-8020
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		46,525,493
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Amendment Flag	false

BALANCE SHEETS

BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 308,454	$ 59,173
Accounts Receivable, Net, Current	60,454	55,815
Inventory, Net	109,795	77,084
Other	12,743	10,398
Total current assets	491,446	202,470
Property, Plant and Equipment, Net	62,667	65,515
Intangible Assets, Net (Excluding Goodwill)	81,714	90,336
Goodwill	118,145	118,145
Operating Lease, Right-of-Use Asset	18,799	20,439
Deferred Income Tax Assets, Net	21,175	27,702
Other Assets, Noncurrent	16,999	19,122
Total assets	810,945	543,729
Current liabilities:
Accounts payable	17,201	17,983
Accrued Liabilities, Current	48,849	31,872
Short-term unearned revenue	10,192	8,214
Total current liabilities	76,242	58,069
Long-term unearned revenue	1,515	1,633
Operating Lease, Liability, Noncurrent	14,485	17,182
Other long-term liabilities	2,094	1,985
Total liabilities	294,848	78,869
Stockholders' Equity Attributable to Parent [Abstract]
Common Stock, Value, Outstanding	46	44
Preferred Stock, Value, Outstanding	0	0
Additional Paid in Capital	428,628	380,304
Accumulated Other Comprehensive Income (Loss), Net of Tax	(837)	(1,380)
Retained earnings	88,260	85,892
Stockholders' Equity Attributable to Parent	516,097	464,860
Liabilities and Equity	810,945	543,729
Long-term Debt	$ 200,512	$ 0

BALANCE SHEETS (Parenthetical)

BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common Stock, Shares, Issued		44,325,369
Common Stock, Shares, Outstanding	45,617,807	44,325,369
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0

INCOME STATEMENTS

INCOME STATEMENTS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Revenues	$ 106,060	$ 78,673	$ 306,003	$ 244,137
Cost of Goods and Services Sold	42,679	36,833	122,595	111,263
Gross margin	63,381	41,840	183,408	132,874
Research and development	14,074	13,262	39,855	43,295
Selling, General and Administrative Expense	34,862	31,448	102,987	96,085
Amortization of Intangible Assets	2,919	2,852	8,623	8,556
Operating Expenses	51,855	47,562	151,465	147,936
Operating income	11,526	(5,722)	31,943	(15,062)
Other income, net	(4,506)	2	(6,889)	(96)
Income (Loss) Attributable to Parent, before Tax	6,563	(5,720)	23,704	(15,158)
Provision for income taxes	(4,796)	470	(8,773)	7,937
Net Income (Loss) Attributable to Parent	1,767	(5,250)	14,931	(7,221)
Net Income (Loss) Available to Common Stockholders, Basic	1,734	(5,224)	14,637	(7,187)
Net Income (Loss) Available to Common Stockholders, Diluted	$ 1,733	$ (5,224)	$ 14,638	$ (7,189)
Earnings Per Share [Abstract]
Earnings Per Share, Basic	$ 0.04	$ (0.12)	$ 0.33	$ (0.16)
Earnings Per Share, Diluted	$ 0.04	$ (0.12)	$ 0.32	$ (0.16)
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Weighted Average Number of Shares Outstanding, Basic	45,459	44,216	44,920	44,109
Weighted Average Number of Shares Outstanding, Diluted	46,343	44,216	45,777	44,109
Common Stock, Dividends, Per Share, Declared	$ 0.09	$ 0.09	$ 0.27	$ 0.21
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	$ 526	$ (454)	$ 543	$ (496)
Other Comprehensive Income (Loss), Net of Tax	526	(454)	543	(496)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	2,293	(5,704)	15,474	(7,717)
Income (Loss) from Equity Method Investments	$ (457)	$ 0	$ (1,350)	$ 0

INCOME STATEMENTS INCOME STATEM

INCOME STATEMENTS INCOME STATEMENTS (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Operating Expenses	$ 51,855	$ 47,562	$ 151,465	$ 147,936
Operating Income (Loss)	$ 11,526	$ (5,722)	$ 31,943	$ (15,062)

CASH FLOWS STATEMENTS

CASH FLOWS STATEMENTS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Net Cash Provided by (Used in) Operating Activities [Abstract]
Net Income (Loss) Attributable to Parent	$ 1,767	$ (5,250)	$ 14,931	$ (7,221)
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Depreciation, Depletion and Amortization	7,690	7,177	22,771	21,170
Amortization of Debt Issuance Costs	2,565	0	3,910	0
Stock-based compensation expense	4,072	3,565	10,781	9,644
Increase (Decrease) in Deferred Income Taxes	2,310	(2,316)	4,635	(10,970)
Gain (Loss) on Disposition of Property Plant Equipment	(40)	59	346	231
Income (Loss) from Equity Method Investments	(457)	0	(1,350)	0
Other Operating Activities, Cash Flow Statement	833	(510)	836	(532)
Changes in operating assets and liabilities:
Accounts receivable	228	13,459	(4,636)	7,563
Inventories	(17,366)	(6,617)	(32,660)	(12,602)
Operating Assets	(1,530)	567	(339)	3,971
Operating Liabilities	13,223	600	15,500	(6,956)
Accounts payable	1,170	372	(322)	4,540
Unearned revenue	(435)	(1,661)	1,901	(610)
Net cash from operations	14,944	9,445	39,004	8,228
Net Cash Provided by (Used in) Financing Activities [Abstract]
Proceeds from Convertible Debt	0	0	252,247	0
Common stock issued	9,924	695	19,366	2,481
Payments Related to Tax Withholding for Share-based Compensation	(32)	(4)	(2,365)	(2,089)
Common stock cash dividends paid	(4,137)	(2,703)	(12,297)	(8,098)
Payments for Hedge, Financing Activities	0	0	(54,626)	0
Proceeds from Issuance of Warrants	0	0	19,968	0
Net cash used in financing	5,755	(2,012)	222,293	(7,706)
Net Cash Provided by (Used in) Investing Activities [Abstract]
Additions to property and equipment	(3,515)	(4,993)	(11,614)	(13,115)
Proceeds from Divestiture of Businesses and Interests in Affiliates	0	0	22	0
Proceeds from Previous Acquisition	0	0	0	1,915
Net cash used in investing	(3,515)	(4,993)	(11,592)	(11,200)
Effect of foreign exchange rates on cash and cash equivalents	(395)	286	(424)	288
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total	16,789	2,726	249,281	(10,390)
Cash and cash equivalents, end of period	$ 308,454	$ 66,051	$ 308,454	$ 66,051

STOCKHOLDERS' EQUITY STATEMENTS

STOCKHOLDERS' EQUITY STATEMENTS - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated other comprehensive Income (loss)	Retained earnings
Stockholders' Equity Attributable to Parent	$ 467,656	$ 44	$ 365,349	$ (1,127)	$ 103,390
Common Stock, Shares, Issued	43,899,210
Stock Issued During Period, Value, Stock Options Exercised	$ 298	$ 0	298	0	0
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures		204,216
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures	(2,072)	$ 0	(2,072)	0	0
Stock-based compensation expense	2,449	0	2,449	0	0
Net Income (Loss) Attributable to Parent	2,960	$ 0	0	0	2,960
Common stock cash dividends	(2,701)		25		(2,726)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		16,707
Net Income (Loss) Attributable to Parent	(7,221)
Stockholders' Equity Attributable to Parent	468,457	$ 44	366,049	(1,260)	103,624
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax	$ (133)	0	0	(133)	0
Common Stock, Shares, Outstanding	44,120,133
Common Stock, Shares, Outstanding	44,120,133
Stock Issued During Period, Value, Stock Options Exercised	$ 499	$ 0	499	0	0
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures		11,033
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures	(13)	$ 0	(13)	0	0
Stock-based compensation expense	3,630	0	3,630	0	0
Net Income (Loss) Attributable to Parent	(4,931)	$ 0	0	0	(4,931)
Common stock cash dividends	(2,705)		27		(2,732)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		28,327
Stock Issued During Period, Shares, Employee Stock Purchase Plans		53,865
Stock Issued During Period, Value, Employee Stock Purchase Plan	966	$ 0	966	0	0
Stockholders' Equity Attributable to Parent	465,994	44	371,158	(1,169)	95,961
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax	$ 91	0	0	91	0
Common Stock, Shares, Outstanding	44,213,358
Common Stock, Shares, Outstanding	44,213,358
Stock Issued During Period, Value, Stock Options Exercised	$ 124	$ 0	124	0	0
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures		1,507
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures	(4)	$ 0	(4)	0	0
Stock-based compensation expense	3,565	0	3,565	0	0
Net Income (Loss) Attributable to Parent	(5,250)	$ 0	0	0	(5,250)
Common stock cash dividends	(4,068)		29		(4,097)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		7,283
Stockholders' Equity Attributable to Parent	459,907	$ 44	374,872	(1,623)	86,614
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax	$ (454)	0	0	(454)	0
Common Stock, Shares, Outstanding	44,222,148
Common Stock, Shares, Outstanding	44,222,148
Stockholders' Equity Attributable to Parent	$ 464,860	44	380,304	(1,380)	85,892
Common Stock, Shares, Outstanding	44,325,369
Common Stock, Shares, Issued	44,325,369
Common Stock, Shares, Outstanding	44,325,369
Stock Issued During Period, Value, Stock Options Exercised	$ 782	$ 0	782	0	0
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures		224,435
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures	(2,309)	$ 1	(2,310)	0	0
Stock-based compensation expense	2,683	0	2,683	0	0
Net Income (Loss) Attributable to Parent	654	$ 0	0	0	654
Common stock cash dividends	(4,101)		42		(4,143)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		52,604
Net Income (Loss) Attributable to Parent	14,931
Stockholders' Equity Attributable to Parent	462,506	$ 45	381,501	(1,443)	82,403
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax	$ (63)	0	0	(63)	0
Common Stock, Shares, Outstanding	44,602,408
Common Stock, Shares, Outstanding	44,602,408
Stock Issued During Period, Value, Stock Options Exercised	$ 7,507	$ 0	7,507	0	0
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures		11,665
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures	(22)	$ 0	(22)	0	0
Stock-based compensation expense	4,026	0	4,026	0	0
Net Income (Loss) Attributable to Parent	12,510	$ 0	0	0	12,510
Common stock cash dividends	(4,140)		45		(4,185)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		363,878
Stock Issued During Period, Shares, Employee Stock Purchase Plans		64,100
Stock Issued During Period, Value, Employee Stock Purchase Plan	1,119	$ 0	1,119	0	0
Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt	41,950		41,950
Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments	(41,243)		(41,243)
Adjustments to Additional Paid in Capital, Warrant Issued	19,968		19,968
Stockholders' Equity Attributable to Parent	504,261	45	414,851	(1,363)	90,728
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax	$ 80	0	0	80	0
Common Stock, Shares, Outstanding	45,042,051
Common Stock, Shares, Outstanding	45,042,051
Stock Issued During Period, Value, Stock Options Exercised	$ 9,689	$ 1	9,688	0	0
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures		2,837
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures	(32)	$ 0	(32)	0	0
Stock-based compensation expense	4,073	0	4,073	0	0
Net Income (Loss) Attributable to Parent	1,767	$ 0	0	0	1,767
Common stock cash dividends	(4,187)		48		(4,235)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		572,919
Stockholders' Equity Attributable to Parent	516,097	$ 46	428,628	(837)	88,260
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax	$ 526	$ 0	$ 0	$ 526	$ 0
Common Stock, Shares, Outstanding	45,617,807
Common Stock, Shares, Outstanding	45,617,807

ACCUMULATED OTHER COMPREHENSIVE

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Comprehensive Income (Loss) Note [Text Block]	NOTE 7 — OTHER COMPREHENSIVE (LOSS) INCOME Other comprehensive (loss) income represents a measure of all changes in equity that result from recognized transactions and other economic events other than those resulting from investments by, and distributions to, shareholders. Other comprehensive (loss) income for the Company includes foreign currency translation adjustments and net unrealized holding gains and losses on available-for-sale investments. The following table presents the changes in each component of accumulated other comprehensive (loss) income, net of tax (in thousands): Accumulated Other Comprehensive (Loss) Income Items - Foreign Currency Balance as of December 31, 2019 $ (1,380) Other comprehensive income 543 Net current-period other comprehensive income 543 Balance as of September 30, 2020 $ (837) There are no material tax benefits or expenses related to the other comprehensive income for the three and nine months ended September 30, 2020.

INVESTMENTS (Details)

INVESTMENTS (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Document Period End Date	Sep. 30, 2020
Cost Method Investments, Original Cost		$ 11,501
Prepaid Expense and Other Assets, Noncurrent	$ 1,258	1,594
Other Assets, Noncurrent	$ 16,999	19,122
Cost Method Investments, Additional Information	The Company owned a minority interest in another private company based in the U.S. through its initial investment of $1.0 million in the third quarter of 2012. We were informed that this private company was dissolving and ceasing operations in 2019. We recorded impairments of $160,000 and $45,000 in Other income, net in the Consolidated Statements of Comprehensive Income during the second quarter and fourth quarter of 2019, respectively. We received the final cash payment for the remainder of our investment in the first quarter of 2020, recorded in Cash flows from investing activities in the Consolidated Statements of Cash Flows.These investments do not have readily determinable fair values. Therefore, the Company has elected the measurement alternative for its minority interests and the investments are recorded at cost, less any impairment, including changes resulting from observable price changes. The Company regularly evaluates the carrying value of its investments for impairment and whether any events or circumstances are identified that would significantly harm the fair value of these investments. The primary indicators the Company utilizes to identify these events and circumstances are the investee’s ability to remain in business, such as the investee’s liquidity and rate of cash use, and the investee’s ability to secure additional funding and the value of that additional funding. In the event a decline in fair value is less than the investment’s carrying value, the Company will record an impairment charge in Other income, net in the Consolidated Statements of Comprehensive Income. Other than the aggregate $205,000 impairment in 2019 discussed above, the Company has not recorded any impairment charges related to these non-marketable investments.As the inputs utilized for the Company’s periodic impairment assessment are not based on observable market data, the determination of fair value of these investments is classified within Level 3 of the fair value hierarchy. See Note 5 - Fair Value Measurement to our Condensed Consolidated Financial Statements for further information on the fair value hierarchy and the three classification levels. To determine the fair value of these investments, the Company uses all available financial information related to the entities, including information based on recent or pending third-party equity investments in these entities. In certain instances, an investment’s fair value is not estimated as there are no identified events or changes in the circumstances. There have been no unrealized gains or losses related to these Level 3 minority interest investments.
Equity Method Investment, Additional Information	Non-Marketable Securities and Other-Than-Temporary ImpairmentDuring the year ended December 31, 2018, the Company made a $1.8 million investment in Combinati, a private company. On October 1, 2019 the Company made an additional $7.0 million investment in Combinati, bringing the Company's ownership to approximately 28.4% of the voting interest of Combinati. Effective October 1, 2019, the Company accounted for its investment in Combinati under the equity method, given the Company's significant influence over the investee due to its larger ownership percentage and its participation on Combinati’s board of directors. The Company does not have unilateral decision-making power, and therefore does not consolidate the investee. In the fourth quarter of 2019, the Company remeasured the existing, minority interest investment based on the fair value prior to the additional investment and recorded a gain of approximately $3.2 million in Other income, net in the Consolidated Statements of Comprehensive Income. The minority interest investment in Combinati was reclassified to equity method investments to distinguish it from other minority interest investments that take the fair value alternative.As of September 30, 2020, the carrying value of the Company’s total investment in Combinati was $10.2 million, which exceeded the Company’s share of Combinati’s net assets by approximately $8.0 million. For the quarter ended September 30, 2020, the Company recorded $0.5 million for its allocable share of Combinati’s net loss in its Consolidated Statement of Comprehensive Income and as an adjustment to the invested balance.
Money Market Funds, at Carrying Value	$ 707	707
Available-for-sale Securities, Current	707	707
Available-for-sale Securities	707	707
Licensing Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Net	$ 5,590	$ 6,027

ACCUMULATED OTHER COMPREHENSI_2

ACCUMULATED OTHER COMPREHENSIVE INCOME (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Net of Tax	$ (837)		$ (837)		$ (1,380)
Other Comprehensive Income (Loss), Net of Tax	$ 526	$ (454)	$ 543	$ (496)

INVENTORIES

INVENTORIES	9 Months Ended
	Sep. 30, 2020
Inventory Disclosure [Abstract]
INVENTORIES	NOTE 3 — INVENTORIES, NET Inventories are stated at the lower of cost or net realizable value, with cost determined according to the standard cost method, which approximates the first-in, first-out method. Net realizable value is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. The Company routinely assesses its on-hand inventory for timely identification and measurement of obsolete, slow-moving or otherwise impaired inventory. Net inventories consisted of the following (in thousands): September 30, 2020 December 31, 2019 Parts and supplies $ 68,550 $ 45,459 Work-in-progress 20,416 15,532 Finished goods 20,829 16,093 $ 109,795 $ 77,084

FAIR VALUE (Notes)

FAIR VALUE (Notes)	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	NOTE 5 — FAIR VALUE MEASUREMENT Accounting Standards Codification (ASC) 820 “Fair Value Measurement” (ASC 820) defines fair value, establishes a framework for measuring fair value under U.S. GAAP and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 describes a fair value hierarchy based on the following three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last unobservable: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company determines the fair value of its investment portfolio assets by obtaining non-binding market prices from its third-party portfolio managers on the last day of the quarter, whose sources may use quoted prices in active markets for identical assets (Level 1 inputs) or inputs other than quoted prices that are observable either directly or indirectly (Level 2 inputs) in determining fair value. There were no transfers between Level 1, Level 2 or Level 3 measurements for the nine-month period ended September 30, 2020. The following table represents the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2020 and December 31, 2019 (in thousands): Fair Value Measurements as of September 30, 2020 Using Level 1 Level 2 Level 3 Total Assets: Money market funds $ 707 $ — $ — $ 707 Equity investment $ — $ — $ 10,151 $ 10,151 Fair Value Measurements as of December 31, 2019 Using Level 1 Level 2 Level 3 Total Assets: Money market funds $ 707 $ — $ — $ 707 Minority interest investments - short-term $ — $ — $ 22 $ 22 Equity investment $ — $ — $ 11,501 $ 11,501

GOODWILL

GOODWILL	9 Months Ended
	Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill Disclosure [Text Block]	NOTE 6 — GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill is reviewed for impairment at least annually at the beginning of the fourth quarter, or more frequently if impairment indicators arise. A portion of the Company’s goodwill is not expected to be deductible for tax purposes. The changes in the carrying amount of goodwill during the period are as follows (in thousands): September 30, 2020 December 31, 2019 Balance at beginning of period $ 118,145 $ 118,127 Flow cytometry acquisition $ — $ 18 Balance at end of period $ 118,145 $ 118,145

INTANGIBLE ASSETS

INTANGIBLE ASSETS	9 Months Ended
	Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets Disclosure [Text Block]	The Company’s intangible assets are reflected in the table below (in thousands, except weighted average lives): Finite-lived Indefinite-lived Technology, trade secrets and know-how Customer lists and contracts Other identifiable intangible assets IP R&D Total 2019 Balance as of December 31, 2018 $ 98,469 $ 23,819 $ 10,655 $ 24,013 $ 156,956 Flow cytometry acquisition (116) (428) 1,154 (4,016) (3,406) Balance as of December 31, 2019 98,353 23,391 11,809 19,997 153,550 Less: accumulated amortization: Accumulated amortization balance as of December 31, 2018 (40,501) (9,036) (2,271) — (51,808) Amortization expense (7,784) (2,428) (1,194) — (11,406) Accumulated amortization balance as of December 31, 2019 (48,285) (11,464) (3,465) — (63,214) Net balance as of December 31, 2019 $ 50,068 $ 11,927 $ 8,344 $ 19,997 $ 90,336 Weighted average life (in years) 11 10 10 2020 Balance as of December 31, 2019 98,353 23,391 11,809 19,997 $ 153,550 Completion of IP R&D projects 2,687 — — (2,687) $ — Balance as of June 30, 2020 101,040 23,391 11,809 17,310 $ 153,550 Less: accumulated amortization: Accumulated amortization balance as of December 31, 2019 (48,285) (11,464) (3,465) — (63,214) Amortization expense (5,905) (1,821) (896) — (8,622) Accumulated amortization balance as of September 30, 2020 (54,190) (13,285) (4,361) — (71,836) Net balance as of September 30, 2020 $ 46,850 $ 10,106 $ 7,448 $ 17,310 $ 81,714 Weighted average life (in years) 11 10 10 The Company currently has two in-process research and development (IP R&D) projects. The first relates to the development of the next generation VERIGENE ® System, VERIGENE II. The Company is targeting the commercial launch of the VERIGENE II System in 2020. The second is a defensive IP R&D project related to the Company’s next generation xMAP ® System, xMAP INTELLIFLEX, which the Company currently believes will launch commercially in the first quarter of 2021. The next generation Guava System (Guava Next Gen System), acquired as part of the Company’s acquisition of EMD Millipore Corporation’s flow cytometry portfolio, was launched commercially in the second quarter of 2020 and transferred from IP R&D to finite-lived technology, trade secrets and know-how and is being amortized. The estimated aggregate amortization expense for the next five fiscal years and thereafter is as follows (in thousands): 2020 (three months) $ 2,919 2021 11,316 2022 10,070 2023 9,721 2024 9,721 Thereafter 20,657 $ 64,404

ACCRUED LIABILITIES (Notes)

ACCRUED LIABILITIES (Notes)	9 Months Ended
	Sep. 30, 2020
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 10 — ACCRUED LIABILITIES Accrued liabilities consisted of the following (in thousands): September 30, 2020 December 31, 2019 Compensation and employee benefits $ 27,871 $ 17,011 Dividends payable 4,235 4,104 Income and other taxes 4,085 1,538 Warranty costs 1,696 1,641 Royalties payable 777 1,335 Current operating lease liabilities 5,915 5,053 Convertible notes interest payable 2,990 — Other 1,280 1,190 $ 48,849 $ 31,872 The following table summarizes the changes in the warranty accrual (in thousands): Accrued warranty costs as of December 31, 2019 $ 1,641 Warranty adjustments/settlements (1,791) Accrual for warranty costs 1,846 Accrued warranty costs as of June 30, 2020 $ 1,696

Debt

Debt	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Long-term Debt	NOTE 11 — CONVERTIBLE SENIOR NOTES In May 2020, the Company issued $260.0 million principal amount of Convertible Senior Notes due in May 2025 (Notes). The interest rates for the Notes is fixed at 3.00% per annum with interest payable semi-annually on May 15 and November 15 of each year, commencing on November 15, 2020. The Notes mature on May 15, 2025, unless earlier redeemed, converted or repurchased in accordance with their terms prior to such date. Each $1,000 of principal amount of the Notes will initially be convertible into 22.8918 shares of the Company's common stock, which is equivalent to an initial conversion price of approximately $43.68 per share. The initial conversion price for each of the Notes is subject to adjustment upon the occurrence of certain specified events. Holders may convert their Notes at their option at any time prior to the close of business on the business day immediately preceding November 15, 2024 only under the following circumstances: • during any calendar quarter commencing after the calendar quarter ending on June 30, 2020 (and only during such calendar quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; • during the five business day period after any five consecutive trading day period (Measurement Period) in which the trading price (as defined in the relevant indenture governing the Notes) per $1,000 principal amount of Notes for each trading day of the Measurement Period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; or • upon the occurrence of specified corporate events, including but not limited to (a) the bankruptcy, insolvency or reorganization of the Company or any of its significant subsidiaries, or (b) the continued failure after five business days to provide a repurchase notice after (i) a public tender offer; (ii) a recapitalization, share exchange or merger where common stock is converted into cash; (iii) a sale/lease/transfer of all or substantially all of the Company’s assets; (iv) stockholder approval of a plan of liquidation; or (v) the delisting of the Company’s common stock. On or after November 15, 2024 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their Notes at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay or deliver cash, shares of its common stock or a combination of cash and shares of its common stock, at the Company’s election. The Company currently intends to settle the principal amount of the Notes in cash, and settle any excess amount with shares of the Company’s common stock, upon conversion. If a fundamental change (as defined in the relevant indenture governing the Notes) occurs prior to the maturity date, holders of each of the Notes may require the Company to repurchase all or a portion of their Notes for cash at a repurchase price equal to 100% of the principal amount of the Notes, plus any accrued and unpaid interest up to, but excluding, the fundamental change repurchase date. As of September 30, 2020, the Notes were not yet convertible. In accounting for the issuance of the Notes, the Company separated each of the Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value, as of the date of issuance, of a similar debt without the conversion feature. The effective interest rate used for the liability component was 8.50%. The liability component of the Notes is recorded in long-term debt, and the interest payable within the next twelve months is recorded in accrued liabilities on the Condensed Consolidated Balance Sheets as of June 30, 2020. The carrying amount of the equity component representing the conversion feature was determined by deducting the fair value of the liability components from the total initial proceeds. The difference between the par amount of the Notes and the carrying amount of the liability component represents debt discounts that are amortized to interest expense over the respective terms of the Notes using the effective interest rate method. The equity components are not remeasured as long as they continue to meet the conditions for equity classification. In accounting for the $7.7 million of issuance costs related to the Notes, the Company allocated the total amount of issuance costs incurred to the liability and equity components in proportion to the allocation of the proceeds from issuance to the liability and equity components. Issuance costs attributable to the liability components are amortized to interest expense over the respective terms of the Notes using the effective interest rate method. The issuance costs attributable to the equity components were netted against the respective equity components in additional paid-in capital. Issuance costs attributable to the liability component, totaling $6.0 million, are being amortized to expense over the expected life of the Notes using the effective interest method. Issuance costs attributable to the equity component related to the conversion feature, totaling $1.7 million, were netted with the equity component. The Notes consist of the following: As of September 30, 2020 Liability component: Principal $ 260,000 Unamortized debt discount (53,760) Unamortized debt issuance costs (5,728) Net carrying amount $ 200,512 Equity component: Net carrying amount $ 41,950 The following table sets forth total interest expense recognized related to the Notes: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Contractual interest expense $ 1,950 $ — $ 2,990 $ — Amortization of debt issuance costs 208 — 315 — Amortization of debt discount 2,358 — 3,596 — Total $ 4,516 $ — $ 6,901 $ — As of September 30, 2020, the remaining period over which the debt discount and debt issuance costs will be amortized was 4.6 years. Convertible Note Hedge Transactions Concurrent with the offering of the Notes, the Company entered into privately negotiated convertible note hedge transactions (Convertible Note Hedge Transactions) with certain financial institutions (Option Counterparties) related to the issuance of the Notes. The Convertible Note Hedge Transactions are generally expected to reduce the potential dilution to the Company’s common stock upon any conversion of Notes or offset any cash payments the Company is required to make in excess of the principal amount of converted Notes. The Company also entered into separate privately negotiated Warrant Transactions with each of the Option Counterparties pursuant to which the Company issued Warrants that will be exercisable into a number of shares of the Company’s common stock at a price per share equal to $69.89, subject to certain adjustments under the terms of the Warrant Transactions. The Warrant Transactions could separately have a dilutive effect on the Company’s common stock if the market value per share of the Company’s common stock exceeds the applicable strike price of the Warrants. However, subject to certain conditions, the Company may elect to settle the Warrants in cash. The Convertible Note Hedge Transactions and the Warrant Transactions are separate transactions, in each case, entered into by the Company with the same Option Counterparties and are not part of the terms of the Notes and will not affect any holder’s rights under the Notes. The holders of the Notes will not have any rights with respect to the Convertible Note Hedge Transactions or Warrant Transactions. The Company used approximately $34.7 million of the net proceeds of the issuance of the Notes to pay the costs of the Convertible Note Hedge Transactions, after such cost was partially offset by the proceeds to the Company from the sale of the Warrants in the Warrant Transactions. The Convertible Note Hedge Transactions and Warrant Transactions do not meet the criteria for derivative accounting as they are indexed to the Company's stock. The amounts paid for the Convertible Note Hedge Transactions and the proceeds received from the Warrant Transactions have been included as a net reduction to additional paid-in capital.

INCOME TAXES

INCOME TAXES	9 Months Ended
	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	NOTE 13 — INCOME TAXES At the end of each interim reporting period, an estimate is made of the effective tax rate expected to be applicable for the full year. The estimated full year’s effective tax rate is used to determine the income tax rate for each applicable interim reporting period. Tax effects of enacted legislation, including changes in the value of deferred tax assets and liabilities, is recognized in the period of the enactment date. The effective tax rate for the nine months ended September 30, 2020 was 37%, including amounts recorded for discrete events. This differs from the statutory rate of 21% primarily from the effect of foreign operations. The Company’s tax expense reflects the full federal, various state, and foreign blended statutory rates. The Company currently expects a 2020 full-year effective tax rate of 35% to 45%, excluding amounts recorded for discrete events, which is increased compared to our estimate of the full-year effective tax rate in the second quarter of 20% to 30%. This increase is a result of a change in the forecast mix of earnings in the Company’s U.S. and foreign jurisdictions and related tax effects pursuant to the provisions of the 2017 Tax Cuts and Jobs Act. The Company will be subject to provisions regarding U.S. federal taxation of foreign intangible income and has included in its estimate of income tax the effects of this tax. The Company is utilizing its net operating losses (NOLs) and tax credits in the U.S., Canada and the Netherlands. In the first and second quarters of 2020, legislation for coronavirus aid and tax relief was enacted in certain of the jurisdictions in which the Company or one of its subsidiaries files income tax returns. The Company recorded an immaterial income tax benefit for the effect of tax relief legislation for its Hong Kong subsidiary in the first quarter of 2020. Tax relief legislation enacted in the first and second quarters of 2020 did not affect the Company’s income tax provision in its other jurisdictions at this time, and thus no discrete tax items in other jurisdictions have been recorded. The Company or one of its subsidiaries files income tax returns in the U.S. federal jurisdiction, Australia, Canada, China, France, Germany, Hong Kong, Japan, the Netherlands, the U.K., and various U.S. states. Due to NOLs, the U.S., Canadian and Netherlands tax returns dating back to 2016, 2007, and 2013, respectively, can still be reviewed by the taxing authorities. The Company does not expect any material changes to the unrecognized tax benefit liability within the next twelve months. The Company recognizes interest and penalties related to uncertain tax positions in the provision for income taxes.

EARNINGS PER SHARE

EARNINGS PER SHARE	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
EARNINGS PER SHARE	NOTE 8 — EARNINGS PER SHARE A reconciliation of the denominators used in computing per share net income (EPS) is as follows (in thousands, except per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Basic: Net income (loss) $ 1,767 $ (5,250) $ 14,931 $ (7,221) Less: allocation to participating securities (33) 26 (294) 34 Net income (loss) attributable to common stockholders $ 1,734 $ (5,224) $ 14,637 $ (7,187) Weighted average common stock outstanding 45,459 44,216 44,920 44,109 Net income (loss) per share attributable to common stockholders $ 0.04 $ (0.12) $ 0.33 $ (0.16) Diluted: Net income (loss) $ 1,767 $ (5,250) $ 14,931 $ (7,221) Less: allocation to participating securities (34) 26 (293) 32 Net income (loss) attributable to common stockholders $ 1,733 $ (5,224) $ 14,638 $ (7,189) Weighted average common stock outstanding 45,459 44,216 44,920 44,109 Effect of dilutive securities: stock options and awards 884 — 857 — Weighted-average shares used in computing net income (loss) per share 46,343 44,216 45,777 44,109 Net income (loss) per share attributable to common stockholders $ 0.04 $ (0.12) $ 0.32 $ (0.16) Basic net income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of common and common equivalent shares outstanding during the period. Restricted stock awards (RSAs) and stock options to acquire 38,028 and 2,123,497 shares for the three months ended September 30, 2020 and 2019, and 405,928 and 1,502,841 shares for the nine months ended September 30, 2020 and 2019, respectively, were excluded from the computations of diluted earnings per share because the effect of including the RSAs and stock options would have been anti-dilutive.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Shareholders' Equity and Share-based Payments [Text Block]	NOTE 9 — STOCKHOLDERS’ EQUITY AND STOCK-BASED COMPENSATION Dividends On September 10, 2020, the Company’s Board of Directors declared a cash dividend on the Company’s common stock of $0.09 per share. The dividend was payable to stockholders of record as of September 24, 2020 and was paid on October 15, 2020. The Company’s current intention is to pay a continuing dividend on a quarterly basis. However, future declarations of dividends are subject to the final determination of the Company’s Board of Directors. Stock-Based Compensation The Company’s stock option activity for the nine months ended September 30, 2020 is as follows: Stock Options Shares Weighted Average Exercise Price Outstanding at December 31, 2019 3,793 $ 20.17 Granted 1,507 23.09 Exercised (997) 18.18 Canceled or expired (550) 24.43 Outstanding at September 30, 2020 3,753 $ 21.25 The Company had $12.0 million of total unrecognized compensation costs related to stock options at September 30, 2020 that are expected to be recognized over a weighted-average period of 2.83 years. The Company’s restricted share activity for the nine months ended September 30, 2020 is as follows: Restricted Stock Awards (RSAs) Shares Weighted Average Grant Price Non-vested at December 31, 2019 810 $ 22.28 Granted 414 23.25 Vested (293) 21.49 Cancelled or expired (23) 22.44 Non-vested at September 30, 2020 908 $ 22.97 Restricted Stock Units (RSUs) Shares Non-vested at December 31, 2019 522 Granted 97 Vested (45) Cancelled or expired (6) Non-vested at September 30, 2020 568 As of September 30, 2020, there were $17.9 million and $3.4 million of unrecognized compensation costs related to RSAs and RSUs, respectively. These costs are expected to be recognized over a weighted average-period of 2.56 years for the RSAs and 2.23 years for the RSUs. The Company issues a small number of cash-settled RSUs pursuant to the Company’s equity incentive plan in certain foreign countries. These grants do not result in the issuance of common stock and are considered immaterial by the Company. The following are the stock-based compensation costs recognized in the Company’s Condensed Consolidated Statements of Comprehensive Income (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Cost of revenue $ 599 $ 528 $ 1,719 $ 1,489 Research and development 642 549 1,387 1,055 Selling, general and administrative 2,854 2,509 7,777 7,172 Stock-based compensation costs reflected in net income $ 4,095 $ 3,586 $ 10,883 $ 9,716

CONTINGENCIES

CONTINGENCIES	9 Months Ended
	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 14 — COMMITMENTS AND CONTINGENCIES In the normal course of business, the Company is subject to claims, lawsuits and legal proceedings. When it appears probable in management’s judgment, and based upon consultation with outside counsel, that we will incur monetary damages or other costs in connection with any claims or proceedings, and such costs can be reasonably estimated, we record the estimated liability in the financial statements. If only a range of estimated losses can be estimated, we record an amount within the range that, in management’s judgment, reflects the most likely outcome; if none of the estimates within that range is a better estimate than any other amount, we record the liability at the low end of the range of estimates. Any such accrual would be charged to expense in the appropriate period. We disclose significant contingencies when the loss is not probable and/or the amount of the loss is not estimable, when we believe there is at least a reasonable possibility that a loss has been incurred. We recognize costs associated with legal proceedings in the period in which the services were provided. Leases We have leased all of our research, manufacturing and office space and have entered into various other agreements in conducting our business. Our leases have remaining lease terms of 1 year to 6 years, and some of our leases include options to extend the leases for up to 10 years, tenant improvement allowances, rent holidays and rent escalation clauses. At inception, we determine whether an agreement represents a lease, and at commencement, we evaluate each lease agreement to determine whether the lease is an operating or financing lease. Pursuant to the lease guidance issued by the Financial Accounting Standards Board (FASB), all of the Company’s leases outstanding on January 1, 2019 continued to be classified as operating leases. With the adoption of the new lease guidance, the Company recorded an operating lease right-of-use asset and an operating lease liability on its balance sheet. Right-of-use lease assets represent the Company’s right to use the underlying asset for the lease term and the lease obligation represents the Company’s commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company’s leases do not provide an implicit rate, we have used an estimated incremental borrowing rate of 5.75%, based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or expectations regarding the terms. Variable lease costs such as common area costs and property taxes are expensed as incurred. For all lease agreements, we combine lease and non-lease components. Leases with an initial term of twelve months or less are not recorded on the balance sheet. The components of the lease expense were as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Operating lease cost (a) $ 2,429 $ 2,419 $ 7,251 $ 7,010 (a) Includes short-term lease expense costs, which were immaterial in the three and nine months ended September 30, 2020 and 2019. Supplemental cash flow information related to leases was as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Cash paid for amounts included in the measurement of lease liabilities $ 1,778 $ 1,682 $ 5,208 $ 4,856 Supplemental balance sheet information related to leases was as follows (in thousands): September 30, 2020 December 31, 2019 Operating leases: Operating lease right-of-use assets $ 18,799 $ 20,439 Operating lease liabilities $ 20,400 $ 22,235 Weighted Average Remaining Lease Term 3.71 years 4.36 years Weighted Average Discount Rate 5.75 % 5.75 % Maturities of lease liabilities for the next five fiscal years and thereafter are as follows (in thousands): Operating Leases 2020 (three months) $ 1,807 2021 7,076 2022 5,407 2023 4,377 2024 3,102 Thereafter 934 Total lease payments 22,703 Less: imputed interest (2,303) Lease liabilities at September 30, 2020 $ 20,400

RECENT ACCOUNTING (Notes)

RECENT ACCOUNTING (Notes)	9 Months Ended
	Sep. 30, 2020
Accounting Changes and Error Corrections [Abstract]
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	NOTE 15 — RECENT ACCOUNTING PRONOUNCEMENTS Recently adopted accounting guidance In June 2016, the FASB issued guidance on financial instruments and related credit losses. The guidance requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis. The statement of comprehensive income reflects the measurement of credit losses for newly recognized financial assets, as well as the expected credit losses during the period. The measurement of expected credit losses is based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. The updated guidance is effective for annual periods beginning after December 15, 2019, and is applicable to the Company in fiscal 2020. The Company adopted the new standard effective January 1, 2020. The primary impact for the Company was the timing of recording expected credit losses on its trade receivables. The Company does not have a history of significant credit losses and this guidance did not have a material impact on its consolidated financial statements.
Description of New Accounting Pronouncements Not yet Adopted [Text Block]	Recent accounting guidance not yet adopted In December 2019, the FASB issued final guidance that simplifies the accounting for income taxes by eliminating some exceptions to the general approach in ASC 740, Income Taxes. The guidance amended certain disclosure requirements that had become redundant, outdated or superseded. Additionally, this guidance includes provisions for investment company reporting modernization, amends accounting for the interim period effects of changes in tax laws or rates, and simplifies aspects of the accounting for franchise taxes. The guidance is effective for annual periods beginning after December 15, 2020, and is applicable for the Company in fiscal 2021. Early adoption is permitted. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under U.S. GAAP. This update also amends the guidance for the derivatives scope exception for contracts in an entity's own equity to reduce form-over-substance-based accounting conclusions and requires the application of the if-converted method for calculating diluted earnings per share. The update also requires entities to provide expanded disclosures about the terms and features of convertible instruments and how the instruments have been reported in the entity’s financial statements. The guidance is effective for interim and annual periods beginning after December 15, 2021. Early adoption is permitted, but no earlier than January 1, 2021. The Company is currently evaluating the impact of this standard on its condensed consolidated financial statements and related disclosures.

REVENUE RECOGNITION (Notes)

REVENUE RECOGNITION (Notes)	9 Months Ended
	Sep. 30, 2020
Revenue Recognition and Deferred Revenue [Abstract]
Revenue Recognition, Deferred Revenue [Policy Text Block]	NOTE 12 — REVENUE RECOGNITION The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606 “Revenue from Contracts with Customers” (the Standard), the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of the Standard, the Company assesses the goods or services promised within each contract, identifies the performance obligations and assesses whether each promised good or service is distinct. The Company allocates the total transaction price to each performance obligation in an amount based on the estimated relative standalone selling price of the promised good or service underlying each performance obligation and recognizes this as revenue when such performance obligation is satisfied. U.S. Government Contracts In March 2020, the Biomedical Advanced Research and Development Authority (BARDA) awarded the Company two milestone-based contracts, with a value of $642,450 each, funding approximately 36% of the overall cost of development. BARDA is part of the U.S. Department of Health and Human Services (HHS) and is tasked with protecting the U.S. against emerging infectious diseases and other threats. Through public-private partnerships, BARDA supports the development of vaccines, drugs, and diagnostics. One of BARDA’s current goals is to develop medical countermeasures to enhance health security and protect against 2019 novel coronavirus disease (COVID-19) infections. The Company’s management believes these two contracts help to enable an expansion of the Company’s current portfolio of diagnostics for SARS-CoV-2 (the virus that causes COVID-19). The Company recorded government contract revenue of $642,450 in each of the quarters ended March 31, 2020 and June 30, 2020 as all of the milestones were completed for the first BARDA contract in the first quarter and for the second BARDA contract in the second quarter. In September 2020, BARDA awarded the Company two additional milestone-based contracts valued at $5,389,813 and $683,500, respectively, related to completing a 510(k) filing for Luminex’s expanded NxTAG ® Respiratory Pathogen Panel (RPP), which will include the SARS-CoV-2 virus for COVID-19 testing and to support the enhancement of the Company’s xMAP ® SARS-CoV-2 Multi-Antigen IgG Assay. The Company intends to submit this enhanced serology assay for an Emergency Use Authorization (EUA) when this project is completed. No government contract revenue has been recorded to date for either of these two BARDA contracts. Contract assets are included within accounts receivables, net and contract liabilities are included in deferred revenue on the Company’s Condensed Consolidated Balance Sheets. The following table presents the opening and closing balances of the Company’s contract assets and liabilities as of September 30, 2020 (in thousands): Balance as of September 30, 2020 Balance as of December 31, 2019 Contract assets: Unbilled receivables - Royalties $ 11,747 $ 12,257 Total contract assets $ 11,747 $ 12,257 Contract liabilities - Short-term: Deferred revenue - Service $ 9,564 $ 7,771 Deferred revenue - Licenses 197 207 Deferred revenue - Instruments — 2 Deferred revenue - Other 431 234 Total contract liabilities - Short-term $ 10,192 $ 8,214 Contract liabilities - Long-term: Deferred revenue - Service $ 998 $ 968 Deferred revenue - Licenses 517 665 Total contract liabilities - Long-term $ 1,515 $ 1,633 During the nine months ended September 30, 2020, the Company recognized the following revenues as a result of changes in the contract asset and contract liability balances in the period (in thousands): Nine Months Ended September 30, 2020 Revenue recognized in the period: Amounts included as contract liabilities at the beginning of the period $ 4,961 Performance obligations satisfied in previous periods -

ACCOUNTING POLICIES (Policies)

ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Business Description and Accounting Policies [Text Block]	NOTE 1 — BASIS OF PRESENTATION The accompanying unaudited condensed consolidated financial statements have been prepared by Luminex Corporation (the Company or Luminex) in accordance with United States generally accepted accounting principles (U.S. GAAP) for interim financial information and the rules and regulations of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, all adjustments (consisting of normal recurring entries) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020. These financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 (the 2019 10-K).

Receivables, Loans, Notes Recei

Receivables, Loans, Notes Receivable, and Others (Policies)	9 Months Ended
	Sep. 30, 2020
Receivables [Abstract]
Accounts Receivable	NOTE 4 — ACCOUNTS RECEIVABLE AND RESERVES The Company adopted the new credit loss standard effective January 1, 2020. The primary impact for the Company was the timing of recording expected credit losses on its trade receivables. The Company’s allowance for doubtful accounts is based upon its expected credit losses, which is based upon its historical loss experience. Management prepared an analysis of partner versus non-partner credit loss experience and noted that its loss experience between partners and non-partners was very comparable. These receivables have been pooled together, as similar risk characteristics exist between them. Accounts receivable consisted of the following (in thousands): September 30, 2020 December 31, 2019 Accounts receivable 61,808 56,956 Less: Allowance for doubtful accounts (1,354) (1,141) 60,454 55,815 Balance as of December 31, 2019 $ 1,141 Net increases charged to costs and expenses 494 Write-offs of uncollectible accounts (281) Balance as of September 30, 2020 $ 1,354

INVESTMENTS (Tables)

INVESTMENTS (Tables)	9 Months Ended
	Sep. 30, 2020
Investments, Debt and Equity Securities [Abstract]
Other Investments Not Readily Marketable [Table Text Block]	September 30, 2020 December 31, 2019 Purchased technology rights (net of accumulated amortization of $8,736 and $8,300 on September 30, 2020 and December 31, 2019, respectively) $ 5,590 $ 6,027 Minority interest investments 10,151 11,501 Other 1,258 1,594 $ 16,999 $ 19,122
Marketable Securities [Table Text Block]	Amortized Cost Gains in Accumulated Other Comprehensive Income Losses in Accumulated Other Comprehensive Income Estimated Fair Value Current: Money market funds $ 707 $ — $ — $ 707 Total current securities 707 — — 707 Total available-for-sale securities $ 707 $ — $ — $ 707
Investments and Other Noncurrent Assets [Text Block]	NOTE 2 — INVESTMENTS AND OTHER ASSETS Marketable Securities The Company determines the appropriate classification of any investments in debt and equity securities at the time of purchase and re-evaluates such determinations at each balance sheet date. As of September 30, 2020, the Company had no short or long-term investments. Available-for-sale securities consisted of the following as of September 30, 2020 (in thousands): Amortized Cost Gains in Accumulated Other Comprehensive Income Losses in Accumulated Other Comprehensive Income Estimated Fair Value Current: Money market funds $ 707 $ — $ — $ 707 Total current securities 707 — — 707 Total available-for-sale securities $ 707 $ — $ — $ 707 Available-for-sale securities consisted of the following as of December 31, 2019 (in thousands): Amortized Cost Gains in Accumulated Other Comprehensive Income Losses in Accumulated Other Comprehensive Income Estimated Fair Value Current: Money market funds $ 707 $ — $ — $ 707 Total current securities 707 — — 707 Total available-for-sale securities $ 707 $ — $ — $ 707 There were no proceeds from the sales of available-for-sale securities for the three and nine months ended September 30, 2020 or the year ended December 31, 2019. Realized gains and losses on sales of investments are determined using the specific identification method and are included in Other income, net in the Condensed Consolidated Statements of Comprehensive Income. There were no available-for-sale debt securities as of September 30, 2020 or December 31, 2019. All of the Company’s available-for-sale securities with gross unrealized losses as of September 30, 2020 had been in a loss position for less than 12 months. Non-Marketable Securities and Other-Than-Temporary Impairment During the year ended December 31, 2018, the Company made a $1.8 million investment in Combinati, a private company. On October 1, 2019 the Company made an additional $7.0 million investment in Combinati, bringing the Company's ownership to approximately 28.4% of the voting interest of Combinati. Effective October 1, 2019, the Company accounted for its investment in Combinati under the equity method, given the Company's significant influence over the investee due to its larger ownership percentage and its participation on Combinati’s board of directors. The Company does not have unilateral decision-making power, and therefore does not consolidate the investee. In the fourth quarter of 2019, the Company remeasured the existing, minority interest investment based on the fair value prior to the additional investment and recorded a gain of approximately $3.2 million in Other income, net in the Consolidated Statements of Comprehensive Income. The minority interest investment in Combinati was reclassified to equity method investments to distinguish it from other minority interest investments that take the fair value alternative. As of September 30, 2020, the carrying value of the Company’s total investment in Combinati was $10.2 million, which exceeded the Company’s share of Combinati’s net assets by approximately $8.0 million. For the quarter ended September 30, 2020, the Company recorded $0.5 million for its allocable share of Combinati’s net loss in its Consolidated Statement of Comprehensive Income and as an adjustment to the invested balance. The Company owned a minority interest in another private company based in the U.S. through its initial investment of $1.0 million in the third quarter of 2012. We were informed that this private company was dissolving and ceasing operations in 2019. We recorded impairments of $160,000 and $45,000 in Other income, net in the Consolidated Statements of Comprehensive Income during the second quarter and fourth quarter of 2019, respectively. We received the final cash payment for the remainder of our investment in the first quarter of 2020, recorded in Cash flows from investing activities in the Consolidated Statements of Cash Flows. These investments do not have readily determinable fair values. Therefore, the Company has elected the measurement alternative for its minority interests and the investments are recorded at cost, less any impairment, including changes resulting from observable price changes. The Company regularly evaluates the carrying value of its investments for impairment and whether any events or circumstances are identified that would significantly harm the fair value of these investments. The primary indicators the Company utilizes to identify these events and circumstances are the investee’s ability to remain in business, such as the investee’s liquidity and rate of cash use, and the investee’s ability to secure additional funding and the value of that additional funding. In the event a decline in fair value is less than the investment’s carrying value, the Company will record an impairment charge in Other income, net in the Consolidated Statements of Comprehensive Income. Other than the aggregate $205,000 impairment in 2019 discussed above, the Company has not recorded any impairment charges related to these non-marketable investments. As the inputs utilized for the Company’s periodic impairment assessment are not based on observable market data, the determination of fair value of these investments is classified within Level 3 of the fair value hierarchy. See Note 5 - Fair Value Measurement to our Condensed Consolidated Financial Statements for further information on the fair value hierarchy and the three classification levels. To determine the fair value of these investments, the Company uses all available financial information related to the entities, including information based on recent or pending third-party equity investments in these entities. In certain instances, an investment’s fair value is not estimated as there are no identified events or changes in the circumstances. There have been no unrealized gains or losses related to these Level 3 minority interest investments. Other long-term assets consisted of the following (in thousands): September 30, 2020 December 31, 2019 Purchased technology rights (net of accumulated amortization of $8,736 and $8,300 on September 30, 2020 and December 31, 2019, respectively) $ 5,590 $ 6,027 Minority interest investments 10,151 11,501 Other 1,258 1,594 $ 16,999 $ 19,122 For the nine months ended September 30, 2020 and 2019, the Company recognized amortization expenses related to the amortization of purchased technology rights of approximately $437,000 and $500,000, respectively. Future amortization expenses are estimated to be $135,000 in the remaining three months of 2020, $540,000 in 2021, $522,000 in 2022, $505,000 in 2023, $501,000 in 2024 and $3,387,000 thereafter.
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	Marketable Securities The Company determines the appropriate classification of any investments in debt and equity securities at the time of purchase and re-evaluates such determinations at each balance sheet date. As of September 30, 2020, the Company had no short or long-term investments. Available-for-sale securities consisted of the following as of September 30, 2020 (in thousands): Amortized Cost Gains in Accumulated Other Comprehensive Income Losses in Accumulated Other Comprehensive Income Estimated Fair Value Current: Money market funds $ 707 $ — $ — $ 707 Total current securities 707 — — 707 Total available-for-sale securities $ 707 $ — $ — $ 707 Available-for-sale securities consisted of the following as of December 31, 2019 (in thousands): Amortized Cost Gains in Accumulated Other Comprehensive Income Losses in Accumulated Other Comprehensive Income Estimated Fair Value Current: Money market funds $ 707 $ — $ — $ 707 Total current securities 707 — — 707 Total available-for-sale securities $ 707 $ — $ — $ 707 There were no proceeds from the sales of available-for-sale securities for the three and nine months ended September 30, 2020 or the year ended December 31, 2019. Realized gains and losses on sales of investments are determined using the specific identification method and are included in Other income, net in the Condensed Consolidated Statements of Comprehensive Income. There were no available-for-sale debt securities as of September 30, 2020 or December 31, 2019. All of the Company’s available-for-sale securities with gross unrealized losses as of September 30, 2020 had been in a loss position for less than 12 months.

INVENTORIES (Tables)

INVENTORIES (Tables)	9 Months Ended
	Sep. 30, 2020
Inventory Disclosure [Abstract]
Components of Inventories	September 30, 2020 December 31, 2019 Parts and supplies $ 68,550 $ 45,459 Work-in-progress 20,416 15,532 Finished goods 20,829 16,093 $ 109,795 $ 77,084

FAIR VALUE (Tables)

FAIR VALUE (Tables)	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]	Fair Value Measurements as of September 30, 2020 Using Level 1 Level 2 Level 3 Total Assets: Money market funds $ 707 $ — $ — $ 707 Equity investment $ — $ — $ 10,151 $ 10,151

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	9 Months Ended
	Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets and Goodwill [Table Text Block]	Finite-lived Indefinite-lived Technology, trade secrets and know-how Customer lists and contracts Other identifiable intangible assets IP R&D Total 2019 Balance as of December 31, 2018 $ 98,469 $ 23,819 $ 10,655 $ 24,013 $ 156,956 Flow cytometry acquisition (116) (428) 1,154 (4,016) (3,406) Balance as of December 31, 2019 98,353 23,391 11,809 19,997 153,550 Less: accumulated amortization: Accumulated amortization balance as of December 31, 2018 (40,501) (9,036) (2,271) — (51,808) Amortization expense (7,784) (2,428) (1,194) — (11,406) Accumulated amortization balance as of December 31, 2019 (48,285) (11,464) (3,465) — (63,214) Net balance as of December 31, 2019 $ 50,068 $ 11,927 $ 8,344 $ 19,997 $ 90,336 Weighted average life (in years) 11 10 10 2020 Balance as of December 31, 2019 98,353 23,391 11,809 19,997 $ 153,550 Completion of IP R&D projects 2,687 — — (2,687) $ — Balance as of June 30, 2020 101,040 23,391 11,809 17,310 $ 153,550 Less: accumulated amortization: Accumulated amortization balance as of December 31, 2019 (48,285) (11,464) (3,465) — (63,214) Amortization expense (5,905) (1,821) (896) — (8,622) Accumulated amortization balance as of September 30, 2020 (54,190) (13,285) (4,361) — (71,836) Net balance as of September 30, 2020 $ 46,850 $ 10,106 $ 7,448 $ 17,310 $ 81,714 Weighted average life (in years) 11 10 10
Estimated Future Amortization Expense Related to Intangible Assets	2020 (three months) $ 2,919 2021 11,316 2022 10,070 2023 9,721 2024 9,721 Thereafter 20,657 $ 64,404

ACCRUED LIABILITIES (Tables)

ACCRUED LIABILITIES (Tables)	9 Months Ended
	Sep. 30, 2020
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	September 30, 2020 December 31, 2019 Compensation and employee benefits $ 27,871 $ 17,011 Dividends payable 4,235 4,104 Income and other taxes 4,085 1,538 Warranty costs 1,696 1,641 Royalties payable 777 1,335 Current operating lease liabilities 5,915 5,053 Convertible notes interest payable 2,990 — Other 1,280 1,190 $ 48,849 $ 31,872
Schedule of Product Warranty Liability [Table Text Block]	Accrued warranty costs as of December 31, 2019 $ 1,641 Warranty adjustments/settlements (1,791) Accrual for warranty costs 1,846 Accrued warranty costs as of June 30, 2020 $ 1,696

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Basic and Diluted Earnings Per Share	Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Basic: Net income (loss) $ 1,767 $ (5,250) $ 14,931 $ (7,221) Less: allocation to participating securities (33) 26 (294) 34 Net income (loss) attributable to common stockholders $ 1,734 $ (5,224) $ 14,637 $ (7,187) Weighted average common stock outstanding 45,459 44,216 44,920 44,109 Net income (loss) per share attributable to common stockholders $ 0.04 $ (0.12) $ 0.33 $ (0.16) Diluted: Net income (loss) $ 1,767 $ (5,250) $ 14,931 $ (7,221) Less: allocation to participating securities (34) 26 (293) 32 Net income (loss) attributable to common stockholders $ 1,733 $ (5,224) $ 14,638 $ (7,189) Weighted average common stock outstanding 45,459 44,216 44,920 44,109 Effect of dilutive securities: stock options and awards 884 — 857 — Weighted-average shares used in computing net income (loss) per share 46,343 44,216 45,777 44,109 Net income (loss) per share attributable to common stockholders $ 0.04 $ (0.12) $ 0.32 $ (0.16)

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Inventory, Raw Materials and Purchased Parts, Net of Reserves	$ 68,550	$ 45,459
Inventory, Work in Process, Net of Reserves	20,416	15,532
Inventory, Finished Goods, Net of Reserves	20,829	16,093
Inventory, Net	$ 109,795	$ 77,084

Receivables, Loans, Notes Rec_2

Receivables, Loans, Notes Receivable, and Others (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Receivables [Abstract]
Accounts Receivable, Allowance for Credit Loss, Current	$ 1,354	$ 1,141
Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)	494
Accounts Receivable, Allowance for Credit Loss, Writeoff	$ 281

FAIR VALUE (Details)

FAIR VALUE (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	$ 707	$ 707
Cost Method Investments, Fair Value Disclosure	10,151	11,501
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	707	707
Cost Method Investments, Fair Value Disclosure	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	0	0
Cost Method Investments, Fair Value Disclosure	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	0	0
Cost Method Investments, Fair Value Disclosure	$ 10,151	$ 11,501

GOODWILL (Details)

GOODWILL (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	$ 118,145	$ 118,145	$ 118,127
Goodwill, Acquired During Period	$ 0	$ 18

INTANGIBLE ASSETS (Detail)

INTANGIBLE ASSETS (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year	$ 2,919		$ 2,919
Finite-Lived Intangible Assets, Accumulated Amortization	(71,836)		(71,836)		$ (63,214)	$ (51,808)
Indefinite-lived Intangible Assets (Excluding Goodwill)	17,310		17,310		19,997	24,013
Finite-Lived Intangible Assets, Amortization Expense, after Year Five	20,657		20,657
Finite-Lived Intangible Assets, Amortization Expense, Year Three	10,070		10,070
Finite-Lived Intangible Assets, Amortization Expense, Year Two	11,316		11,316
Finite-Lived Intangible Assets, Amortization Expense, Year Four	9,721		9,721
Finite-Lived Intangible Assets, Amortization Expense, Year Five	9,721		9,721
Intangible Assets, Net (Excluding Goodwill)	81,714		81,714		90,336
Intangible Assets, Gross (Excluding Goodwill)					153,550	156,956
Amortization of Intangible Assets, IA	(2,919)	$ (2,852)	(8,623)	$ (8,556)	(11,406)
Indefinite-lived Intangible Assets, Purchase Accounting Adjustments					(4,016)
Employee Benefits and Share-based Compensation	4,095	$ 3,586	10,883	$ 9,716
Contract with Customer, Liability, Revenue Recognized	4,961
Technology-Based Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Accumulated Amortization	(54,190)		(54,190)		(48,285)	(40,501)
Finite-Lived Intangible Assets, Gross					98,353	98,469
Finite-Lived Intangible Assets, Net	46,850		$ 46,850		$ 50,068
Finite-Lived Intangible Asset, Useful Life			11 years		11 years
Amortization of Intangible Assets, IA			$ (5,905)		$ (7,784)
Finite-Lived Intangible Assets, Purchase Accounting Adjustments					(116)
Customer-Related Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Accumulated Amortization	(13,285)		(13,285)		(11,464)	(9,036)
Finite-Lived Intangible Assets, Gross					23,391	23,819
Finite-Lived Intangible Assets, Net	10,106		$ 10,106		$ 11,927
Finite-Lived Intangible Asset, Useful Life			10 years		10 years
Amortization of Intangible Assets, IA			$ (1,821)		$ (2,428)
Finite-Lived Intangible Assets, Purchase Accounting Adjustments					(428)
Other Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Accumulated Amortization	(4,361)		(4,361)		(3,465)	(2,271)
Finite-Lived Intangible Assets, Gross					11,809	$ 10,655
Finite-Lived Intangible Assets, Net	$ 7,448		$ 7,448		$ 8,344
Finite-Lived Intangible Asset, Useful Life			10 years		10 years
Amortization of Intangible Assets, IA			$ (896)		$ (1,194)
Finite-Lived Intangible Assets, Purchase Accounting Adjustments					$ 1,154

ACCRUED LIABILITIES (Details)

ACCRUED LIABILITIES (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Employee-related Liabilities, Current	$ 27,871	$ 17,011
Taxes Payable, Current	4,085	1,538
Product Warranty Accrual, Current	1,696	1,641
Accrued Royalties, Current	777	1,335
Operating Lease, Liability, Current	5,915	5,053
Interest Payable, Current	2,990	0
Standard and Extended Product Warranty Accrual, Decrease for Payments	(1,846)
Standard and Extended Product Warranty Accrual, Increase for Warranties Issued	1,791
Dividends Payable, Current	4,235	4,104
Other Accrued Liabilities, Current	1,280	1,190
Accrued Liabilities, Current	$ 48,849	$ 31,872

Debt (Details)

Debt (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Debt Disclosure [Abstract]
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate	3.00%		3.00%
Long-term Debt, Maturity Date	May 15, 2025		May 15, 2025
Debt Instrument, Convertible, Conversion Price	$ 43.68		$ 43.68
Debt Instrument, Convertible, Stock Price Trigger			$ 69.89
Debt Instrument, Unamortized Discount	$ (53,760)		$ (53,760)
Unamortized Debt Issuance Expense	(5,728)		(5,728)
Long-term Debt, Gross	260,000		260,000
Interest Expense, Debt	$ 4,516	$ 0	$ 6,901	$ 0
Debt Instrument, Convertible, Remaining Discount Amortization Period			4 years 7 months 6 days

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Effective tax rate			37.00%
U.S. federal statutory tax rate			21.00%
Provision for income taxes	$ 4,796	$ (470)	$ 8,773	$ (7,937)
Income (Loss) Attributable to Parent, before Tax	$ 6,563	$ (5,720)	$ 23,704	$ (15,158)

EARNINGS PER SHARE Details (Det

EARNINGS PER SHARE Details (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019
Earnings Per Share [Abstract]
Participating Securities, Distributed and Undistributed Earnings (Loss), Basic	$ (33)			$ 26			$ (294)	$ 34
Net Income (Loss) Available to Common Stockholders, Basic	$ 1,734			$ (5,224)			$ 14,637	$ (7,187)
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	38,028			2,123,497			405,928	1,502,841
Net Income (Loss) Available to Common Stockholders, Diluted	$ 1,733			$ (5,224)			$ 14,638	$ (7,189)
Weighted Average Number of Shares Outstanding, Basic	45,459,000			44,216,000			44,920,000	44,109,000
Earnings Per Share, Basic	$ 0.04			$ (0.12)			$ 0.33	$ (0.16)
Net Income (Loss) Attributable to Parent	$ 1,767	$ 12,510	$ 654	$ (5,250)	$ (4,931)	$ 2,960	$ 14,931	$ (7,221)
Participating Securities, Distributed and Undistributed Earnings (Loss), Diluted	$ (34)			$ 26			$ (293)	$ 32
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements	884,000			0			857,000	0
Weighted Average Number of Shares Outstanding, Diluted	46,343,000			44,216,000			45,777,000	44,109,000
Earnings Per Share, Diluted	$ 0.04			$ (0.12)			$ 0.32	$ (0.16)

STOCKHOLDERS' EQUITY Details (D

STOCKHOLDERS' EQUITY Details (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 12
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	568	522
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	97
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	(45)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	(6)
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 2 months 23 days
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options	$ 3.4
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	908	810
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value	$ 22.97	$ 22.28
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	414
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 23.25
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	(293)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value	$ 21.49
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	(23)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value	$ 22.44
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 6 months 21 days
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options	$ 17.9
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 9 months 29 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	3,753	3,793
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 21.25	$ 20.17
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,507
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 23.09
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	(997)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	$ 18.18
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period	(550)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price	$ 24.43

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Operating Lease, Weighted Average Remaining Lease Term	3 years 8 months 15 days		3 years 8 months 15 days		4 years 4 months 9 days
Lease, Cost	$ 2,429	$ 2,419	$ 7,251	$ 7,010
Operating Leases, Future Minimum Payments, Remainder of Fiscal Year	1,807		1,807
Operating Leases, Future Minimum Payments, Due in Two Years	7,076		7,076
Operating Leases, Future Minimum Payments, Due in Three Years	5,407		5,407
Operating Leases, Future Minimum Payments, Due in Four Years	4,377		4,377
Operating Leases, Future Minimum Payments, Due in Five Years	3,102		3,102
Operating Leases, Future Minimum Payments, Due Thereafter	934		934
Operating Leases, Future Minimum Payments Due	$ 22,703		$ 22,703
Operating Lease, Weighted Average Discount Rate, Percent	5.75%		5.75%		5.75%
Operating Lease, Payments	$ 1,778	$ 1,682	$ 5,208	$ 4,856

REVENUE RECOGNITION (Details)

REVENUE RECOGNITION (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue Recognition and Deferred Revenue [Abstract]
Lease, Cost	$ 2,429	$ 2,419	$ 7,251	$ 7,010